Sam Brusco, Associate Editor06.07.22
Abbott presented late-breaking clinical data at this year’s American Diabetes Association meeting showing its FreeStyle Libre 3 continuous glucose monitoring (CGM) system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day CGM system to achieve a sub-8% overall MARD.
MARD represents the difference between CGM glucose readings and a reference blood glucose measurement.
"Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology -- the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate," Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott's diabetes care business told the press. "A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions."
By age group, MARD values were 7.6% for adults, 8.7% for children 6-17, and 10.1% for children 4-5.
Analysis of retrospective data over 24 months from over 370,000 patients with type 2 diabetes in Canada showed FreeStyle Libre data insights helped clinicians make earlier decisions or adjustments to treatment as well.
MARD represents the difference between CGM glucose readings and a reference blood glucose measurement.
"Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology -- the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate," Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott's diabetes care business told the press. "A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions."
By age group, MARD values were 7.6% for adults, 8.7% for children 6-17, and 10.1% for children 4-5.
Analysis of retrospective data over 24 months from over 370,000 patients with type 2 diabetes in Canada showed FreeStyle Libre data insights helped clinicians make earlier decisions or adjustments to treatment as well.